Clinical Trial Update: Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating recombinant interleukin-21 (rIL-21) for metastases in lymph nodes due to malignant melanoma. The study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• recombinant interleukin-21 (rIL-21) (interleukin-21)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Cancer, Malignant Melanoma | Phase 2 | Status: TERMINATED